Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatory and metabolic diseases, such as chronic gout and non-alcoholic steatohepatitis (NASH) for which there are no effective treatments.

Atom’s lead therapy, ABP-671, for chronic gout, is more potent and significantly less toxic than existing drugs, and is poised to enter global Phase 3 trials in 2022. Another compound, ABP-6016, has demonstrated safety and efficacy in preclinical trials for NASH, which is projected to become the most common cause of liver disease.

Latest News from Atom Bioscience

On Gout Awareness Day, Let’s Put the Myths to Rest
PRESS RELEASE...
BioWorld: Atom Bioscience Planning Phase III Gout Trial After Encouraging Mid-Stage Readout
BioSpace: Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout
Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout
PRESS RELEASE...